The possible molecular mechanism is that intraperitoneally injected GnIH promoted adipogenesis and decreased lipolysis in the liver and WAT via inhibiting the AMPK signal pathway, resulting in hyperlipidemia and obesity (Figure 8). This evidence concerns the gene PRKAB1 and obesity disorder.